

# CHLAMYDIA VACCINE

Innovative vaccine strategy against chlamydia infection

Chlamydia ■ Vaccine ■ Killed bacteria

## APPLICATIONS

- Chlamydia infection prevention in humans
- Veterinary Market : All Chlamydiaceae (Chlamydia & Chlamydophila) infections in different species

## DEVELOPMENT PHASE

Pre-Clinical Phase : *In vivo* proof of concept in mice

Ongoing : evaluation of long term protection effect and reactivation assays

## INTELLECTUAL PROPERTY

Priority patent application filed on 2015

## CONTACT

Davide D'ALIA

Mail : dda@idfinnov.com

Phone : +33(0)7.63.12.71.96

## PRESENTATION

With more than 100 million cases every year, Chlamydia infection continues to be the most commonly reported sexually transmitted bacterial infection in many countries, especially for women. Current treatments with antibiotics are not completely effective against chlamydia infection and there is no available vaccine in the market at this stage.

Chlamydia infection is also a problem among pets or livestock animals. Indeed, a large range of animals can be infected with some Chlamydia strains and there is no prophylactic immunization that gives a 100% protection.

The present offer proposes a vaccine candidate for the prevention of chlamydia infections. The vaccine candidate involves **killed form of Chlamydia with presence of native antigens**. Mice infected with Chlamydia muridarum after vaccination present no lesion in genital organs compared to control mice (with no vaccination).



Genital organs aspect following infection after Chlamydia infection alone (left) or with vaccine (right) © Kanellopoulos-Langevin

## COMPETITIVE ADVANTAGES

- Killed form vaccine
- Highly immunogenic form
- Prevent chlamydia-induced lesions